Search Results for: cost

Interview with Regenerative Surgeon, Dr. Allan Wu

Over the last few weeks, I have enjoyed talking with and interviewing Dr. Allan Wu, of The Morrow Institute on stem cell cosmetic procedures. I was impressed greatly by his talk at the World Stem Cell Summit last year. Dr. Wu is a fellowship trained Surgical Molecular Biologist with a background in Molecular Embryology and a board …

Interview with Regenerative Surgeon, Dr. Allan Wu Read More »

Some 2012 papers that raise serious safety concerns about adult stem cell treatments

Just how safe are stem cell transplants? Is an autologous stem cell transplant always safe? Is it really true, as one stem cell transplant doc once said of autologous stem cell treatments, that “the worst thing that could happen is the treatment won’t work”? Are adult stem cell treatments by definition safe? The reality is …

Some 2012 papers that raise serious safety concerns about adult stem cell treatments Read More »

Want to get human stem cells intended for clinical use legally across the border? It ain’t gonna be easy

A big issue in the stem cell field is that firms increasingly are doing business in multiple countries. Associated with the increasingly international nature of the stem cell for-profit industry are emerging legal and ethical issues related to the transport of stem cell-based biological drugs across international borders. Think you can just FedEx human stem …

Want to get human stem cells intended for clinical use legally across the border? It ain’t gonna be easy Read More »

Interview with NeoStem CEO Robin Smith Part 2: VSEL, ES cells, and iPS cells

I recently did a Q&A interview with NeoStem CEO Dr. Robin Smith. I posted Part 1 of that interview a few days ago here. Now we have part two focused on VSEL, ES cells, and iPS cells. PK: I frequently have readers of my blog ask questions about VSEL. They seem puzzled and unsure of …

Interview with NeoStem CEO Robin Smith Part 2: VSEL, ES cells, and iPS cells Read More »

Taboo topics about iPS cells: updated for 2013

elephant-in-the-lab-covid-19-lab-ramp-up

I’m doing this series called “The Elephant in the Lab” where I discuss controversial or taboo laboratory topics that people are usually too afraid to publicly discuss.  I started with iPS cells (for a description and definition of iPS cells go here) and now have updated this post for 2013 because the field is changing rapidly. iPS …

Taboo topics about iPS cells: updated for 2013 Read More »

Eight simple reasons not to get an unlicensed stem cell treatment: #4, undesired tissue growth (e.g. bone in your eye)

So far in my series of eight simple reasons not to get an unlicensed stem cell treatment I’ve covered three compelling reasons: potential loss of insurance coverage for negative outcomes that could cost hundreds of thousands of dollars, failure of patient follow up by the doctors and clinics, and exclusion from future clinical trial participation. …

Eight simple reasons not to get an unlicensed stem cell treatment: #4, undesired tissue growth (e.g. bone in your eye) Read More »

Frank panel on hidden dangers of stem cell treatments to patients at WSCS2012

This morning here at The World Stem Cell Summit there was a healthy, frank discussion of the risks associated with receiving unlicensed, unproven stem cell therapies. Dr. Jim Guest presented first and gave a great talk about the risks associated with stem cell treatments. One such risk that was mentioned is inadequate characterization of stem …

Frank panel on hidden dangers of stem cell treatments to patients at WSCS2012 Read More »

8 simple reasons not to get an unlicensed stem cell treatment part 2: lack of follow-up

I’m doing a series of posts on straightforward reasons why patients should not get unlicensed stem cell treatments. Part 1 of the series was on the risk of losing medical insurance coverage. Today is part 2, which is focused on a serious failing of many for-profit, point-of-care stem cell clinics selling unlicensed treatments: lack of …

8 simple reasons not to get an unlicensed stem cell treatment part 2: lack of follow-up Read More »